At-home electrical brain stimulation for Parkinson's movement symptoms
Official title: Virtual Remote Assessment of Transcranial Electrical Stimulation for Parkinson's Disease Motor Symptoms
Run by U: The Mind Company · NCT07182058 · Data updated 2026-11-12
This trial tests a wearable, at-home electrical stimulation device called Sphere V3.0 to see if it improves movement problems in adults with Parkinson's disease.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | U: The Mind Company Industry-sponsored |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | March 1, 2026 |
| Study ends | April 1, 2026 |
| Registry record updated | January 27, 2026 |
| Trial ID | NCT07182058 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–80 with a confirmed Parkinson's diagnosis, Hoehn & Yahr stages 1–4, stable medications for at least four weeks, reliable internet access, and ability to follow telehealth instructions are ideal candidates.
✕Probably not a fit
People with metallic head/neck implants, recent stroke or brain injury, a history of epilepsy, severe cognitive impairment, or severe skin problems at electrode sites may not be suitable or receive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This fully remote Phase 1/2 trial sends the Sphere V3.0 device to participants to use at home for 13 minutes each weekday over three weeks, followed by three weeks of monitoring without treatment. The device delivers amplitude‑modulated transcranial pulsed random noise stimulation (am‑tPRNS) through a four‑electrode array and built‑in safety features. Outcomes include standard Parkinson's rating scales and computer‑vision analysis of standardized and participant‑recorded videos of walking and tremor/hand tasks. The study enrolls 30 adults (ages 18–80) with stable Parkinson's medications and uses telehealth visits for onboarding and assessments.
Why it matters
Potential benefit: If successful, the device could reduce tremor, rigidity, slowness, or gait problems and offer a convenient at‑home therapy option.
How similar studies have gone: Prior work with this stimulation approach has enrolled over 250 participants with extensive hours of use and favorable safety reports, but robust, published evidence of clinical benefit remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults 18-80 years with confirmed diagnosis of Parkinson's Disease * Hoehn \& Yahr stages 1-4 * Stable medication regimen for 4+ weeks prior to enrollment * Reliable internet access and telehealth capability * Ability to provide informed consent * Willingness to comply with treatment protocols and follow-up procedures Exclusion Criteria: * Metallic head/neck implants (excluding dental fillings) * Pregnancy or nursing status * Severe skin conditions at electrode placement sites * History of epilepsy or seizures (unless technology specifically indicated) * Recent stroke or traumatic brain injury (within 6 months) * Severe cognitive impairment preventing treatment understanding * Any neurological disorders contraindicating transcranial electrical stimulation * Current participation in other clinical trials * Inability to commit to full treatment and follow-up schedule
Where it's running
-
U LLC Headquarters
Cleveland, Ohio, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
UX-DA003 injections for Parkinson's disease
This early-phase trial tests whether injecting UX-DA003 is safe and may help motor symptoms in people with Parkinson's whose response to standard treatments has declined.
-
Strength and dual-task training to help people with Parkinson’s improve strength and function
This trial tests three levels of physiotherapy, including progressive resistance training with and without cognitive dual-task and instability components, to see if they improve muscle strength, body composition, and physical function in adults with Parkinson’s or related syndromes.
-
Spinal Mobility, Rigidity, and Kinesiophobia in Parkinson's Disease with and without TMD
This study tests whether people with Parkinson's disease who have Temporomandibular Disorders differ in spinal mobility, axial rigidity, and kinesiophobia from those without TMD.
-
A 12-Week Trial of Flexilev with the OraFID Device and App for Parkinson's
This study tests whether taking small, precise doses of Flexilev with the OraFID dosing device and Levilog app is acceptable and helps people with Parkinson's manage their medicine.
-
Integrated Motor-Cognitive Training in Parkinson's Disease
This study tests a combined motor and cognitive rehabilitation program to see if people with Parkinson’s disease can stick with it and show early signs of benefit.
-
VIM0423 for Parkinson's Tremor in Adults Not Fully Controlled by Dopaminergic Therapy
A Vima Therapeutics study tests whether the oral drug VIM0423 can reduce tremor in adults with Parkinson’s disease who still have tremor despite dopaminergic treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.